4 Healthcare Stock Stories Not To Be Overlooked

Prana Biotechnology (NASDAQ:PRAN): Current price $2.50

The company has announced that PBT434, its lead drug candidate for Parkinson’s Disease and movement disorders, will be presented at two international conferences in March. The key finding to be discussed is that PBT434 lowers the aggregation and accumulation of a key protein (alpha-synuclein) in multiple transgenic animal models of the disease. The alpha-synuclein (s.n.) protein aggregates inside the nerve cells of the substantia nigra, the part of the brain that is progressively damaged in the disease. The substantia nigra is responsible for controlling movement. The (s.n.) protein aggregates are associated with the onset and progression of Parkinson’s Disease and in three different Parkinson’s Disease animal models, PBT434 significantly prevented the death of substantia nigra brain cells.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.